Retrospective analysis of the efficacy of gemcitabine for previously treated AIDS-associated kaposi's sarcoma in Western Kenya

R. Matthew Strother, Kelly M. Gregory, Sonak D. Pastakia, Pamela Were, Constance Tenge, Naftali Busakhala, Beatrice Jakait, Ellen M. Schellhase, Alan G. Rosmarin, Patrick Loehrer

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objectives: Evaluation of outcomes in the use of single-agent gemcitabine for the treatment of AIDS-associated Kaposi's sarcoma (KS) in a western Kenyan cancer treatment program. Methods: Retrospective chart review of all patients with KS treated with single agent gemcitabine following failure of first-line Adriamycin, bleomycin, and vincristine (ABV). Baseline demographics were collected, and clinicians' assessments of response were utilized to fill out objective criteria for both response as well as symptom benefit assessment. Results: Twenty-three patients with KS who had previously failed first-line therapy with ABV were evaluated. Following treatment, 22 of the 23 patients responded positively to treatment with stable disease or better. Of the 18 patients who had completed therapy, with a median follow-up of 5 months, 12 patients had no documented progression. Conclusions: Treatment options in the resource-constrained setting are limited, both by financial constraints as well as the need to avoid myelotoxicity, which is associated with high morbidity in this treatment setting. This work shows that gemcitabine has promising activity in KS, with both objective responses and clinical benefit observed in this care setting. Gemcitabine as a single agent merits further investigation for AIDS-associated KS.

Original languageEnglish
Pages (from-to)5-11
Number of pages7
JournalOncology
Volume78
Issue number1
DOIs
StatePublished - Mar 2010

Fingerprint

gemcitabine
Kaposi's Sarcoma
Kenya
Acquired Immunodeficiency Syndrome
Bleomycin
Vincristine
Therapeutics
Doxorubicin
Symptom Assessment

Keywords

  • Gemcitabine
  • Sarcoma
  • Second-line chemotherapy
  • Tolerability
  • Treatment outcome

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Retrospective analysis of the efficacy of gemcitabine for previously treated AIDS-associated kaposi's sarcoma in Western Kenya. / Strother, R. Matthew; Gregory, Kelly M.; Pastakia, Sonak D.; Were, Pamela; Tenge, Constance; Busakhala, Naftali; Jakait, Beatrice; Schellhase, Ellen M.; Rosmarin, Alan G.; Loehrer, Patrick.

In: Oncology, Vol. 78, No. 1, 03.2010, p. 5-11.

Research output: Contribution to journalArticle

Strother, RM, Gregory, KM, Pastakia, SD, Were, P, Tenge, C, Busakhala, N, Jakait, B, Schellhase, EM, Rosmarin, AG & Loehrer, P 2010, 'Retrospective analysis of the efficacy of gemcitabine for previously treated AIDS-associated kaposi's sarcoma in Western Kenya', Oncology, vol. 78, no. 1, pp. 5-11. https://doi.org/10.1159/000292356
Strother, R. Matthew ; Gregory, Kelly M. ; Pastakia, Sonak D. ; Were, Pamela ; Tenge, Constance ; Busakhala, Naftali ; Jakait, Beatrice ; Schellhase, Ellen M. ; Rosmarin, Alan G. ; Loehrer, Patrick. / Retrospective analysis of the efficacy of gemcitabine for previously treated AIDS-associated kaposi's sarcoma in Western Kenya. In: Oncology. 2010 ; Vol. 78, No. 1. pp. 5-11.
@article{b6c4fb0bb1304ca4a918c75f5fd5f54f,
title = "Retrospective analysis of the efficacy of gemcitabine for previously treated AIDS-associated kaposi's sarcoma in Western Kenya",
abstract = "Objectives: Evaluation of outcomes in the use of single-agent gemcitabine for the treatment of AIDS-associated Kaposi's sarcoma (KS) in a western Kenyan cancer treatment program. Methods: Retrospective chart review of all patients with KS treated with single agent gemcitabine following failure of first-line Adriamycin, bleomycin, and vincristine (ABV). Baseline demographics were collected, and clinicians' assessments of response were utilized to fill out objective criteria for both response as well as symptom benefit assessment. Results: Twenty-three patients with KS who had previously failed first-line therapy with ABV were evaluated. Following treatment, 22 of the 23 patients responded positively to treatment with stable disease or better. Of the 18 patients who had completed therapy, with a median follow-up of 5 months, 12 patients had no documented progression. Conclusions: Treatment options in the resource-constrained setting are limited, both by financial constraints as well as the need to avoid myelotoxicity, which is associated with high morbidity in this treatment setting. This work shows that gemcitabine has promising activity in KS, with both objective responses and clinical benefit observed in this care setting. Gemcitabine as a single agent merits further investigation for AIDS-associated KS.",
keywords = "Gemcitabine, Sarcoma, Second-line chemotherapy, Tolerability, Treatment outcome",
author = "Strother, {R. Matthew} and Gregory, {Kelly M.} and Pastakia, {Sonak D.} and Pamela Were and Constance Tenge and Naftali Busakhala and Beatrice Jakait and Schellhase, {Ellen M.} and Rosmarin, {Alan G.} and Patrick Loehrer",
year = "2010",
month = "3",
doi = "10.1159/000292356",
language = "English",
volume = "78",
pages = "5--11",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "1",

}

TY - JOUR

T1 - Retrospective analysis of the efficacy of gemcitabine for previously treated AIDS-associated kaposi's sarcoma in Western Kenya

AU - Strother, R. Matthew

AU - Gregory, Kelly M.

AU - Pastakia, Sonak D.

AU - Were, Pamela

AU - Tenge, Constance

AU - Busakhala, Naftali

AU - Jakait, Beatrice

AU - Schellhase, Ellen M.

AU - Rosmarin, Alan G.

AU - Loehrer, Patrick

PY - 2010/3

Y1 - 2010/3

N2 - Objectives: Evaluation of outcomes in the use of single-agent gemcitabine for the treatment of AIDS-associated Kaposi's sarcoma (KS) in a western Kenyan cancer treatment program. Methods: Retrospective chart review of all patients with KS treated with single agent gemcitabine following failure of first-line Adriamycin, bleomycin, and vincristine (ABV). Baseline demographics were collected, and clinicians' assessments of response were utilized to fill out objective criteria for both response as well as symptom benefit assessment. Results: Twenty-three patients with KS who had previously failed first-line therapy with ABV were evaluated. Following treatment, 22 of the 23 patients responded positively to treatment with stable disease or better. Of the 18 patients who had completed therapy, with a median follow-up of 5 months, 12 patients had no documented progression. Conclusions: Treatment options in the resource-constrained setting are limited, both by financial constraints as well as the need to avoid myelotoxicity, which is associated with high morbidity in this treatment setting. This work shows that gemcitabine has promising activity in KS, with both objective responses and clinical benefit observed in this care setting. Gemcitabine as a single agent merits further investigation for AIDS-associated KS.

AB - Objectives: Evaluation of outcomes in the use of single-agent gemcitabine for the treatment of AIDS-associated Kaposi's sarcoma (KS) in a western Kenyan cancer treatment program. Methods: Retrospective chart review of all patients with KS treated with single agent gemcitabine following failure of first-line Adriamycin, bleomycin, and vincristine (ABV). Baseline demographics were collected, and clinicians' assessments of response were utilized to fill out objective criteria for both response as well as symptom benefit assessment. Results: Twenty-three patients with KS who had previously failed first-line therapy with ABV were evaluated. Following treatment, 22 of the 23 patients responded positively to treatment with stable disease or better. Of the 18 patients who had completed therapy, with a median follow-up of 5 months, 12 patients had no documented progression. Conclusions: Treatment options in the resource-constrained setting are limited, both by financial constraints as well as the need to avoid myelotoxicity, which is associated with high morbidity in this treatment setting. This work shows that gemcitabine has promising activity in KS, with both objective responses and clinical benefit observed in this care setting. Gemcitabine as a single agent merits further investigation for AIDS-associated KS.

KW - Gemcitabine

KW - Sarcoma

KW - Second-line chemotherapy

KW - Tolerability

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=77649290654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649290654&partnerID=8YFLogxK

U2 - 10.1159/000292356

DO - 10.1159/000292356

M3 - Article

C2 - 20215784

AN - SCOPUS:77649290654

VL - 78

SP - 5

EP - 11

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 1

ER -